Table 4.

Change of total symptom and sign scores after administration (ITT/PP dataset)

Variables	ITT				PP
	Treatment groupa	Control groupb	F-value	P-value	Treatment groupa	Control groupb	F-value	P-value
Baseline
TSI, mean ± SD	17.75 ± 5.71	17.98 ± 5.45	0.1726	0.6782	17.86 ± 5.80	17.91 ± 5.52	0.02	0.8983
Visit 1 (3rd day), mean ± SD
TSI	14.19 ± 5.80	14.03 ± 5.11	0.0155	0.9009	14.25 ± 5.92	13.82 ± 5.15	0.21	0.6447
DTB	3.56 ± 3.51	3.95 ± 4.03	0.5795	0.4473	3.61 ± 3.59	4.09 ± 3.86	0.67	0.4147
Visit 2 (7th day), mean ± SD
TSI	9.91 ± 5.08	9.90 ± 4.77	0.0093	0.9231	9.75 ± 5.16	9.41 ± 4.40	0.12	0.7279
DTB	7.84 ± 4.72	8.08 ± 5.27	0.1318	0.7169	8.11 ± 4.69	8.50 ± 4.87	0.22	0.6420
Visit 3 (14th day), mean ± SD
TSI	5.71 ± 4.31	6.06 ± 4.91	0.4706	0.4935	5.41 ± 4.16	5.30 ± 3.98	0.04	0.8329
DTB	12.04 ± 5.58	11.92 ± 5.97	0.0114	0.9153	12.45 ± 5.33	12.61 ± 5.37	0.00	0.9945
Visit 4 (21st day), mean ± SD
TSI	2.50 ± 3.32	3.16 ± 4.80	2.24	0.1361	2.06 ± 2.71	2.32 ± 3.09	0.70	0.4033
DTB	15.25 ± 6.05	14.82 ± 6.57	0.19	0.6609	15.80 ± 5.59	15.59 ± 5.78	0.08	0.7771

Notes:

^aTreatment group = ganciclovir in situ ophthalmic gel group;

^bcontrol group = ganciclovir ophthalmic gel group.

Abbreviations: ITT, intent-to-treat; PP, per-protocol; TSI, total scores of clinical indicators; SD, standard deviation; DTB, decrease of total scores of clinical indicators from baseline.